Choreo LLC Has $363,000 Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Choreo LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 58.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,954 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,087 shares during the period. Choreo LLC’s holdings in Jazz Pharmaceuticals were worth $363,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning raised its holdings in Jazz Pharmaceuticals by 21.7% during the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after acquiring an additional 680 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $213,000. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares during the period. Inspire Investing LLC acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at $312,000. Finally, Exchange Traded Concepts LLC increased its holdings in Jazz Pharmaceuticals by 21.8% in the third quarter. Exchange Traded Concepts LLC now owns 6,890 shares of the specialty pharmaceutical company’s stock valued at $768,000 after purchasing an additional 1,233 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $135.44 on Thursday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market cap of $8.19 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $136.55. The firm’s fifty day simple moving average is $122.97 and its two-hundred day simple moving average is $116.89.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JAZZ shares. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Piper Sandler restated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Finally, Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $177.00.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 5,053 shares of company stock worth $617,442. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.